Literature DB >> 29754320

Pathophysiology and Genetics of Bronchiectasis Unrelated to Cystic Fibrosis.

Aleksandra Nikolic1.   

Abstract

Bronchiectasis is characterized by deregulated inflammatory response and recurrent bacterial infection resulting in progressive lung damage and an irreversible dilatation of bronchi and bronchioles. Generally accepted model of the development of bronchiectasis is the "vicious cycle hypothesis" that proposes compromising of the mucociliary clearance by an initial event, which leads to the infection of the respiratory tract followed by further impairment of mucociliary function, bacterial proliferation, and more inflammation. Bronchiectasis is a very common symptom in patients with cystic fibrosis (CF), while bronchiectasis unrelated to CF is heterogeneous pathology of unknown cause with a large number of potential contributory factors and poorly understood pathogenesis. It is presumed that bronchiectasis unrelated to CF is a multifactorial condition predisposed by genetic factors. Different molecules have been implicated in the onset and development of idiopathic bronchiectasis, as well as modulation of the disease severity and response to therapy. Most of these molecules are involved in the processes that contribute to the homeostasis of the lung tissue, especially mucociliary clearance, protease-antiprotease balance, and immunomodulation. Evaluation of the studies performed towards investigation of the role these molecules play in bronchiectasis identifies genetic variants that may be of potential importance for clinical management of the disease, and also of interest for future research efforts. This review focuses on the molecules with major roles in lung homeostasis and their involvement in bronchiectasis unrelated to CF.

Entities:  

Keywords:  Bronchiectasis; Genetics; Pathophysiology

Mesh:

Substances:

Year:  2018        PMID: 29754320     DOI: 10.1007/s00408-018-0121-y

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  106 in total

1.  Trends in bronchiectasis among medicare beneficiaries in the United States, 2000 to 2007.

Authors:  Amy E Seitz; Kenneth N Olivier; Jennifer Adjemian; Steven M Holland; D Rebecca Prevots
Journal:  Chest       Date:  2012-08       Impact factor: 9.410

2.  Novel cftr gene sequence variation in Serbian patient with idiopathic disseminated bronchiectasis.

Authors:  Aleksandra Nikolic; Katarina Milosevic; Aleksandra Divac; Mila Ljujic; Slobodanka Grkovic; Branimir Nestorovic
Journal:  Fetal Pediatr Pathol       Date:  2010-01       Impact factor: 0.958

3.  CFTR gene variant IVS8-5T in disseminated bronchiectasis.

Authors:  P F Pignatti; C Bombieri; M Benetazzo; A Casartelli; E Trabetti; L S Gilè; L C Martinati; A L Boner; M Luisetti
Journal:  Am J Hum Genet       Date:  1996-04       Impact factor: 11.025

4.  Mutations of DNAI1 in primary ciliary dyskinesia: evidence of founder effect in a common mutation.

Authors:  Maimoona A Zariwala; Margaret W Leigh; Franck Ceppa; Marcus P Kennedy; Peadar G Noone; Johnny L Carson; Milan J Hazucha; Adriana Lori; Judit Horvath; Heike Olbrich; Niki T Loges; Anne-Marie Bridoux; Gaëlle Pennarun; Bénédicte Duriez; Estelle Escudier; Hannah M Mitchison; Rahul Chodhari; Eddie M K Chung; Lucy C Morgan; Robbert U de Iongh; Jonathan Rutland; Ugo Pradal; Heymut Omran; Serge Amselem; Michael R Knowles
Journal:  Am J Respir Crit Care Med       Date:  2006-07-20       Impact factor: 21.405

5.  Increased incidence of cystic fibrosis gene mutations in adults with disseminated bronchiectasis.

Authors:  P F Pignatti; C Bombieri; C Marigo; M Benetazzo; M Luisetti
Journal:  Hum Mol Genet       Date:  1995-04       Impact factor: 6.150

6.  Presence, activities, and molecular forms of cathepsin G, elastase, alpha 1-antitrypsin, and alpha 1-antichymotrypsin in bronchiectasis.

Authors:  R Sepper; Y T Konttinen; T Ingman; T Sorsa
Journal:  J Clin Immunol       Date:  1995-01       Impact factor: 8.317

7.  High resolution computed tomography (HRCT) in emphysema associated with alpha-1-antitrypsin deficiency.

Authors:  P J Guest; D M Hansell
Journal:  Clin Radiol       Date:  1992-04       Impact factor: 2.350

8.  Mannose-binding lectin gene polymorphic variants predispose to the development of bronchopulmonary complications but have no influence on other clinical and laboratory symptoms or signs of common variable immunodeficiency.

Authors:  J Litzman; T Freiberger; B Grimbacher; B Gathmann; U Salzer; T Pavlík; J Vlcek; V Postránecká; Z Trávnícková; V Thon
Journal:  Clin Exp Immunol       Date:  2008-07-11       Impact factor: 4.330

9.  Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype.

Authors:  Julie Toubiana; Satoshi Okada; Julia Hiller; Matias Oleastro; Macarena Lagos Gomez; Juan Carlos Aldave Becerra; Marie Ouachée-Chardin; Fanny Fouyssac; Katta Mohan Girisha; Amos Etzioni; Joris Van Montfrans; Yildiz Camcioglu; Leigh Ann Kerns; Bernd Belohradsky; Stéphane Blanche; Aziz Bousfiha; Carlos Rodriguez-Gallego; Isabelle Meyts; Kai Kisand; Janine Reichenbach; Ellen D Renner; Sergio Rosenzweig; Bodo Grimbacher; Frank L van de Veerdonk; Claudia Traidl-Hoffmann; Capucine Picard; Laszlo Marodi; Tomohiro Morio; Masao Kobayashi; Desa Lilic; Joshua D Milner; Steven Holland; Jean-Laurent Casanova; Anne Puel
Journal:  Blood       Date:  2016-04-25       Impact factor: 22.113

Review 10.  Mannose-binding lectin deficiency and respiratory tract infection.

Authors:  Damon P Eisen
Journal:  J Innate Immun       Date:  2009-07-07       Impact factor: 7.349

View more
  1 in total

1.  Aberrant Epithelial Cell Proliferation in Peripheral Airways in Bronchiectasis.

Authors:  Yang Peng; Ai-Ru Xu; Shi-Ying Chen; Yan Huang; Xiao-Rong Han; Wei-Jie Guan; De-Yun Wang; Nan-Shan Zhong
Journal:  Front Cell Dev Biol       Date:  2020-02-20
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.